Auxilium Pharmaceuticals, Inc. 640 Lee Road Chesterbrook, PA 19087
Exhibit 10.2
Auxilium Pharmaceuticals, Inc.
640 Lee Road
Chesterbrook, PA 19087
October 8, 2014
VIA FACSIMILE AND COURIER
QLT Inc.
887 Great Northern Way, Suite 250
Vancouver, BC V5T 4T5
Canada
Attn: Dori Assaly
Facsimile No.: (604) 873-0816
E-mail: ***@***
Re: Notice of Termination
Dear Dori:
Reference is made to the Agreement and Plan of Merger, dated as of June 25, 2014 (the Merger Agreement), by and among Auxilium Pharmaceuticals, Inc. (Auxilium), QLT Inc. (QLT), QLT Holding Corp. and QLT Acquisition Corp, and the transaction contemplated thereby (the Merger). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Merger Agreement.
Pursuant to the Merger Agreement, Auxilium hereby gives notice to QLT that Auxilium has received a proposal from Endo International plc (Endo) that Endo acquire 100% of Auxiliums issued and outstanding shares of common stock pursuant to a merger in which Auxilium stockholders will receive, in respect of each share of Auxilium common stock, at the election of such share of Auxilium common stock (i) $33.25 in cash, (ii) 0.4880 of a share of Endo common stock or (iii) $16.625 in cash and 0.244 of a share of Endo common stock, in the case of clauses (i) and (ii), subject to certain pro-rations (the Endo Proposal).
The Auxilium Board of Directors (the Board) has determined in good faith, after consultation with its financial advisors and outside legal counsel, that the Endo Proposal constitutes an Auxilium Superior Proposal and that a failure to accept the Endo Proposal and terminate the Merger Agreement would be reasonably likely to be inconsistent with the Boards fiduciary duties to Auxilium stockholders under applicable Laws. Accordingly, Auxilium hereby exercises its right to terminate the Merger Agreement pursuant to Section 7.1(c)(ii) thereof, effective immediately.
In accordance with Section 7.2(c)(i) of the Merger Agreement, the Auxilium Termination Fee is concurrently being sent to QLT by wire transfer to the account previously provided to us by your counsel. In addition, in accordance with Section 5.14 of the Merger
Agreement, an amount of $US 49,567.62 (the Cost Reimbursement), representing all reasonable out-of-pocket expenses, fees and expenses incurred by QLT and QLT Subsidiaries in connection with the Pre-Acquisition Reorganization, is being sent to QLT by wire transfer to the same account.
Pursuant to the Non-Disclosure Agreement, Auxilium hereby requests that QLT and its Representatives promptly return to Auxilium, or destroy and confirm such destruction in writing, all Confidential Material and Notes (as such terms are defined in the Non-Disclosure Agreement).
By countersigning below, QLT hereby requests that Auxilium and its Representatives promptly return to QLT, or destroy and confirm such destruction in writing, all Confidential Material and Notes (as such terms are defined in the Non-Disclosure Agreement).
By countersigning below, QLT hereby acknowledges and agrees, on behalf of itself and its Affiliates, that, following and subject to the receipt by QLT of the Auxilium Termination Fee and the Cost Reimbursement, neither Auxilium nor any of its Affiliates shall have any further obligations whatsoever, directly or indirectly, in contract, at law or in equity arising under, relating to or resulting from the Merger Agreement or any transaction contemplated by the Merger Agreement.
Auxilium hereby acknowledges and agrees, on behalf of itself and its Affiliates, that, effective upon QLTs execution and delivery of this Notice of Termination to Auxilium, neither QLT nor any of its Affiliates shall have any further obligations whatsoever, directly or indirectly, in contract, at law or in equity arising under, relating to or resulting from the Merger Agreement or any transaction contemplated by the Merger Agreement. Notwithstanding anything to the contrary in this paragraph or the prior paragraph, the Non-Disclosure Agreement shall remain in full force and effect in accordance with its terms.
In accordance with Section 9.1 of the Merger Agreement, this Notice of Termination shall be effective upon delivery; provided, however, that the immediately preceding three paragraphs shall become effective at the time QLT delivers an executed countersigned copy of this Notice of Termination to Auxilium.
[Signature Page Follows]
2
| Sincerely, |
|
|
| /s/ Andrew I. Koven |
| Andrew I. Koven |
| Chief Administrative Officer, General Counsel and Secretary |
| Auxilium Pharmaceuticals, Inc. |
AGREED AND ACCEPTED,
THIS DAY OF OCTOBER 2014
QLT INC.
/s/ Sukhi Jagpal |
|
Name: Sukhi Jagpal |
|
Title: Chief Financial Officer |
|
cc: McCullough OConnor Irwin LLP
Suite 2600, Oceanic Plaza
1066 West Hastings Street
Vancouver, BC V6E 3X1
Attention: Mia Bacic
James Beeby
Facsimile No.: (604)  ###-###-####
E-mail: ***@***
***@***
Nutter McClennen & Fish, LLP
155 Seaport Boulevard
Boston, MA 02210
Attention: James E. Dawson, Esq.
Facsimile No.: (617)  ###-###-####
E-mail: ***@***
3